Summary
| Company & vaccine name | Versus Wuhan | Versus Variants | Rates of side effects | Severity of side effects | Safety & health risks | Antibody levels | Protection durability | Ease of transport | Ease of administration |
|---|
Efficacy Versus Wuhan Strains (lineage B.1)
| Vaccine | Efficacy Level |
|---|---|
| 1. Novavax | 96.4% to 100% |
| 2. Pfizer | 95% |
| 3. Moderna | 94.1% |
| 4. AstraZeneca | 74% |
| 5. J & J (versus moderate and severe, would be lower % if mild cases were included) |
66% |
Efficacy Versus Variants of Interest and Concern
| Vaccine | Efficacy Level |
|---|---|
| 1. Novavax | 90.2% |
| 2. Pfizer | 85% |
| 3. Moderna | 83.1% |
| 4. AstraZeneca | 64% |
| 5. J & J (versus moderate and severe, would be lower % if mild cases were included) |
61%-81% |
Efficacy Against Severe Disease and Hospitalization
| Vaccine | Efficacy Level |
|---|---|
| 1. Novavax | 100% |
| 2. Pfizer | 100% |
| 3. Moderna | 97% |
| 4. AstraZeneca | 85% |
| 5. J & J | 80% |
Mild and Moderate Side Effects
| Vaccine | Efficacy Level |
|---|
Severe Side Effects
| Vaccine | Efficacy Level |
|---|---|
| 1. | |
| 2. | |
| 3. | |
| 4. | |
| 5. |
Side Effects From Booster Shots
| Side Effects | Novavax | Pfizer | Moderna | AstraZeneca | J & J |
|---|---|---|---|---|---|
| Injection site reaction |
20%
|
30%
|
40%
|
50%
|
100%
|
| Malaise |
34%
|
45%
|
60%
|
50%
|
30%
|
| Broad muscle pain |
54%
|
54%
|
45%
|
45%
|
45%
|
| Fever |
65%
|
56%
|
56%
|
56%
|
56%
|
| Joint pain |
76%
|
67%
|
67%
|
67%
|
67%
|
Neutralizing Antibody Quantities
| Vaccine | Efficacy Level |
|---|---|
| 1. Novavax | 1400 |
| 2. Moderna | 1300 |
| 3. Pfizer | 500 |
| 4. J & J | 450 |
| 5. AstraZeneca (versus moderate and severe, would be lower % if mild cases were included) |
300 |
Declines in Antibody Quantities
Antibodies have a half-life of about 1 month. This means that each month, the quantity of antibodies drops in half. In other words, by 50%. The lower the quantity drops, the lower the efficacy.
| Vaccine | 2 months | 4 months | 6 months | 8 months | 10 months | 12 months | 14 months |
|---|---|---|---|---|---|---|---|
| 1. Novavax | 1400 | 350 | 175 | 87.5 | 43.8 | 21.9 | 10.9 |
| 2. Moderna | 1300 | 325 | 162.5 | 81.3 | 40.6 | 20.3 | 10.2 |
| 3. Pfizer | 500 | 125 | 62.5 | 31.3 | 15.6 | 7.8 | 3.9 |
| 4. J & J | 450 | 112.5 | 56.3 | 28.1 | 14.1 | 7 | 3.5 |
| 5. AstraZeneca (versus moderate and severe, would be lower % if mild cases were included) |
300 | 75 | 37.5 | 18.8 | 9.4 | 4.7 | 2.3 |
Durability : Drops in Efficacy Overtime
Antibodies have a half-life of about 1 month. This means that each month, the quantity of antibodies drops in half. In other words, by 50%. The lower the quantity drops, the lower the efficacy.
| Vaccine | 4 months | 5 months | 6 months | 7 months | 8 months | 9 months | 10 months |
|---|---|---|---|---|---|---|---|
| 1. Novavax | 650 1 2 | 162.5 |